ORIGINAL ARTICLESSevere depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatineMontgomery, Stuart A.a; Kasper, SiegfriedbAuthor Information aImperial College School of Medicine, University of London, London, UK bDepartment of General Psychiatry, Medical University of Vienna, Vienna, Austria Correspondence to Professor Stuart A. Montgomery, MD, PO Box 8751, London W13 8WH, UK E-mail: [email protected] Received 17 May 2006 Accepted 25 January 2007 International Clinical Psychopharmacology: September 2007 - Volume 22 - Issue 5 - p 283-291 doi: 10.1097/YIC.0b013e3280c56b13 Buy Metrics Abstract The efficacy of agomelatine in severe depression has been examined in three positive placebo-controlled studies and in a pooled analysis of the data from the three studies in patients treated with 25–50 mg agomelatine (n=357) and placebo (n=360). Agomelatine was significantly more effective than placebo in a subgroup of patients with severe depression with a severity of 25 or more on the Hamilton Depression Rating Scale 17-item scale in each individual study (P<0.05) and in the pooled analysis (P<0.001). Analysis of the pooled data demonstrated that there was an increase in the magnitude of the agomelatine–placebo difference with increasing severity on the baseline Hamilton Depression Rating Scale. When the population was divided into subgroups using increasing cut-off Hamilton Depression Rating Scale values a significant difference between agomelatine and placebo was observed in each subgroup despite the decreasing numbers of patients with higher severity with a difference of 2.06 rising to 4.45 points on the Hamilton Depression Rating Scale. In conclusion, agomelatine is effective in treating severe depression. © 2007 Lippincott Williams & Wilkins, Inc.